Back to results
US 9,944,711 B2Granted
Antibodies against human CD38
AssigneeGenmab A/S
InventorsMichel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
Life of this patent
Estimating the term…
Abstract
Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
Claims48
A method of inhibiting growth and/or proliferation, or migration, or inducing phagocytosis of a cell expressing CD38, comprising contacting the cell with an antibody that binds to human CD38 (SEQ ID NO:
- 52), wherein the antibody comprises:
- (i) a VH CDR1 having the sequence as set forth in any one of SEQ ID NOs:
- 3, 8, 13, 18, and 23, a VH CDR2 having the sequence as set forth in any one of SEQ ID NOs:
- 4, 9, 14, 19, and 24, a VH CDR3 having the sequence as set forth in any one of SEQ ID NOs:
- 5, 10, 15, 20, and 25, a VL CDR1 having the sequence as set forth in any one of SEQ ID NOs:
- 28, 33, 38, 43, and 48, a VL CDR2 having the sequence as set forth in any one of SEQ ID NOs:
- 29, 34, 39, 44, and 49, and a VL CDR3 having the sequence as set forth in any one of SEQ ID NOs:
- 30, 35, 40, 45, and 50,
- (ii) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 3, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 4, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 5, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 28, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 29, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 30,
- (iii) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 8, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 9, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 10, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 33, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 34, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 35,
- (iv) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 13, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 14, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 15, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 38, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 39, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 40,
- (v) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 18, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 19, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 20, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 43, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 44, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 45, or
- (vi) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 23, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 24, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 25, a VL CDR1 having the sequence as set forth in SEQ ID NO 48, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 49, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 50,
- an immunoconjugate comprising the antibody, or a bispecific antibody comprising the antibody, such that the growth and/or proliferation, or migration of the cell is inhibited, or phagocytosis of the cell is induced.
40 more elements
A method of treating a cancer, inflammatory disorder, immune disorder, or autoimmune disorder involving cells expressing CD38 comprising administering to a subject in need thereof an antibody that binds to human CD38 (SEQ ID NO:
- 52), wherein the antibody comprises:
- (i) a VH CDR1 having the sequence as set forth in any one of SEQ ID NOs:
- 3, 8, 13, 18, and 23, a VH CDR2 having the sequence as set forth in any one of SEQ ID NOs:
- 4, 9, 14, 19, and 24, a VH CDR3 having the sequence as set forth in any one of SEQ ID NOs:
- 5, 10, 15, 20, and 25, a VL CDR1 having the sequence as set forth in any one of SEQ ID NOs:
- 28, 33, 38, 43, and 48, a VL CDR2 having the sequence as set forth in any one of SEQ ID NOs:
- 29, 34, 39, 44, and 49, and a VL CDR3 having the sequence as set forth in any one of SEQ ID NOs:
- 30, 35, 40, 45, and 50,
- (ii) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 3, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 4, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 5, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 28, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 29, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 30,
- (iii) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 8, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 9, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 10, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 33, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 34, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 35,
- (iv) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 13, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 14, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 15, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 38, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 39, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 40,
- (v) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 18, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 19, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 20, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 43, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 44, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 45, or
- (vi) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 23, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 24, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 25, a VL CDR1 having the sequence as set forth in SEQ ID NO 48, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 49, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 50,
- an immunoconjugate comprising the antibody, or a bispecific antibody comprising the antibody.
40 more elements
Dependencies are inferred from the claim text.